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Neuromodulators are endogenous neurochemicals that regulate biophysical
and biochemical processes, which control brain function and behaviour, and
are often the targets of neuropharmacological drugs. Neuromodulator effects
are generally complex partly owing to the involvement of broad innervation,
co-release of neuromodulators, complex intra- and extrasynaptic mechanism,
existence of multiple receptor subtypes and high interconnectivity within the
brain. In this work, we propose an efficient yet sufficiently realistic compu-
tational neural modelling framework to study some of these complex
behaviours. Specifically, we propose a novel dynamical neural circuit model
that integrates the effective neuromodulator-induced currents based on various
experimental data (e.g. electrophysiology, neuropharmacology and voltamme-
try). The model can incorporate multiple interacting brain regions, including
neuromodulator sources, simulate efficiently and easily extendable to large-
scale brain models, e.g. for neuroimaging purposes. As an example, we
model a network of mutually interacting neural populations in the lateral hypo-
thalamus, dorsal raphe nucleus and locus coeruleus, which are major sources of
neuromodulator orexin/hypocretin, serotonin and norepinephrine/noradrena-
line, respectively, and which play significant roles in regulating many
physiological functions. We demonstrate that such a model can provide predic-
tions of systemic drug effects of the popular antidepressants (e.g. reuptake
inhibitors), neuromodulator antagonists or their combinations. Finally, we
developed user-friendly graphical user interface software for model simulation
and visualization for both fundamental sciences and pharmacological studies.1. Introduction
Neuronal activities, through the firing of action potentials and synaptic trans-
missions, can be modulated by endogenous neurochemicals called
neuromodulators, acting through biophysical and biochemical processes [1,2].
These neuromodulators are released by a distinct population of neurons, and
the neuromodulators act on specific receptors which are distributed throughout
the brain [3]. Major neuromodulators include serotonin, dopamine, norepi-
nephrine (NE; or noradrenaline), acetylcholine, orexin (or hypocretin),
endorphins and octopamine [3]. As a consequence of neuromodulation,
neural circuit function can be altered, which in turn can affect cognition,
mood and behaviour [3]. In neuropharmacological drug treatment of neurologi-
cal and neuropsychiatric illnesses, the monoaminergic systems (especially that
of serotonin, dopamine and NE) are often targeted [4]. These are achieved,
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Figure 1. LHA, DRN and LC interactions. Arrows: effective excitatory connec-
tions between any two areas; circles: inhibitory connections. Different colours
denote different brain areas and their respective connection types and the
targeted areas [27–31,35].
rsif.royalsocietypublishing.org
J.R.Soc.Interface
14:20160902
2
 on January 18, 2017http://rsif.royalsocietypublishing.org/Downloaded from for example, by altering the affinity of the associated recep-
tors that influences the release and reuptake mechanism of
the monoaminergic systems [5,6]. As neuromodulators can
also influence the biophysical properties of the neurons and
synapses via multiple receptors with differential affinities,
the complexity level in a neuronal circuit function can be sub-
stantial [7,8]. Experimental work often focuses on a specific
brain region or system (e.g. certain receptor subtype) or
employs a specific experimental methodology specific to the
single level of biological organization (e.g. whole-cell record-
ing at the neuronal level or voltammetric recording at specific
brain region). Thus, it is difficult to reconcile their systemic
implications.
Sufficiently realistic computational neural models can
help us to integrate various data types from different studies,
and can also generate testable predictions. However, model-
ling the detailed biophysical effects of neuromodulators can
be complex and computationally costly [9–11]. In particular,
neuromodulation often involves intracellular signalling pro-
cesses at the pre-synaptic and post-synaptic sites, and can
subsequently affect neuronal firing activities [12,13]. Hence,
such computational models that incorporate these biological
processes can be time-consuming to develop, and with the
multiple model parameters and equations, computationally
intensive to evaluate while posing a considerable challenge
in scalability.
In this work, we propose a novel neural circuit modelling
framework to circumvent such difficulties. To develop a scal-
able model, we make use of neural population-averaged
activity (mean-field like) or firing-rate-typemodels that describe
how the neural population activities depend on the averaged
effective neuromodulator-induced currents. The latter are deter-
mined by neuromodulators’ concentration levels and the
corresponding receptor affinities. Compared with other more
abstract population-averaged firing-rate-type models [14–17],
our model parameters describing the input–output functions
and temporal dynamics are informed and constrained by
data integrated from a variety of experiments, which include
electrophysiology, neuropharmacology, radioimmunoassay,
voltammetry and microdialysis.
We discuss such modelling approach in the context of
developing and simulating a neural circuit model intercon-
nected among the dorsal raphe nucleus (DRN), locus
coeruleus (LC) and lateral hypothalamus areas (LHA),
which are major sources of the important neuromodulators
serotonin (5-HT), NE and orexin, respectively. The motiv-
ations for selecting these brain systems to model are that
they are important in regulating physiological functions
especially in arousal, are known to interact mutually with
each other, and are the targets of several drugs [13,18–21].
In particular, the neuropeptide Ox is known to play an
important role in energy homeostasis, food intake and appe-
tite regulation, neuroendocrine functions and sleep–wake
regulation [22–24]. The monoamine NE is suggested to be
responsible for numerous functions, including stress
response, attention, emotion, motivation, decision-making,
learning, memory and regulation of sleep (e.g. REM) [25–30],
whereas the monoamine 5-HT can affect several physiological
functions that include eating behaviour, emotion, and sleep
regulation [31–33]. Abnormal 5-HT or NE levels are implicated
in mood disorders and anxiety [18,34].
The overlapping roles of these neuromodulators are not sur-
prising, given their mutual interconnectivity, and any targetedneurons could themselves be sources of neuromodulators
(figure 1). We have also purposefully selected the Ox system
as a case study to demonstrate how we can model a neural
system that may not be well characterized (when compared
with NE).
A comprehensive, biologically faithful, yet efficient com-
putational model at the neural circuit level would enable us
to conveniently evaluate, account and predict, at a systems
level, important measurable variables such as the concen-
tration levels of the neuromodulators, the neural population
firing rate activities, the effects of individual or combined
drugs (e.g. reuptake inhibitors or antagonists) and their
interdependencies.
The organization of the rest of the paper is as follows.
We first describe the general modelling framework. Then,
as an example, we demonstrate the steps in modelling
three mutually interacting brain regions and discuss the
simulation results including drug effects. Next, we describe
our user-friendly software for simulating and visualizing
the behaviour of such models. Finally, we summarize the
results and discuss the implications of this study.2. Results
2.1. An integrated modelling framework
To develop a biologically compatible neural circuit model
would require knowledge of electrophysiological proper-
ties of the composing neurons in a specific brain region,
and the nature of the interactions among themselves and
with other neuronal groups. This can include neurons
which themselves release neuromodulators. Modelling the
release-and-reuptake/decay dynamics of the extracellular
concentrations of the neuromodulators would require infor-
mation inferred from in vivo voltammetry or microdialysis
studies at the targeted sites under neuronal stimulation. We
would also need to know how the variation in neuromodulator
concentration can in turn affect neural firing rate activities via
neuromodulator-induced currents, hence requiring knowledge
of firing rate–neuromodulator concentration or firing
rate–current relationships (figure 2). These neuromodulator-
induced currents typically involve relatively slow
metabotropic G-protein-coupled receptor (GPCR) types,
e.g. G-protein-coupled inwardly rectifying potassium (GIRK)
or transient receptor potential (TRP) type cation currents
[y1]
[y2]
[yn] In–i
I2–i
I1–i
Itotal, i fi
Figure 2. Incorporating afferent currents from neuromodulator concentration
levels. [ y1] . . . [ yn] denote the different neuromodulator concentrations. i
represents a particular targeted brain region. I j!i is the corresponding
induced currents to region i. iTotal, i is the total afferent current and fi is
the firing frequency in region i. For example, [ y1] and [ y2] may be the con-
centration levels of serotonin [5-HT] and norepinephrine [NE], and i can be
the lateral hypothalamus LHA. The big arrow denotes ‘closing the loop’ in the
modelling process.
rsif.royalsocietypublishing.org
J.R.Soc.Interface
14:20160902
3
 on January 18, 2017http://rsif.royalsocietypublishing.org/Downloaded from [36,37], on targeted neurons, which alter the neuronal
firing rate activities. As discussed, explicitly modelling such
signalling pathway mechanisms can be complex and compu-
tationally intensive if large-scale neural circuits are involved.
To circumvent such challenges, we turn to phenomenological
yet biologically faithful models to mimic the overall effects.
To begin the modelling process, we first model the neural
activity for each brain region using neural population-
averaged activity [38]. Because the time constant of the typical
neural population firing-rate dynamics is approximately
10–100 ms, it is much faster than the dynamics owing to
neuromodulators, which is approximately seconds to minutes
(table 1). Hence, we shall ignore the neural population
dynamics and assume the system to be dominated by the
slower neuromodulator-induced dynamics [57]. In general,
different neuronal types can respond differently (in terms
of firing rate activity) to the same current injection. In
experiments, such relationship is demonstrated by the fre-
quency–current ( f2 I) relationship. In a similar vein, we can
describe the ith neural population by the population firing
rate–current ( f2 I) curve or input–output function [58]:
fi ¼ FiðItotal,iÞ, (2:1)
where fi is the population firing rate, Fi is the input–output
function and Itotal,i is the total averaged afferent current.
Under typical physiological ranges, it suffices to use a
threshold-linear function [58]:
FiðItotal,iÞ ¼ Ki ½Ii  I0,i þ Ibias,iþ, (2:2)
where [x]þ ¼ x if x. 0, and 0 otherwise. Ki is the constant gain
or slope of the input–output function, I0,i is the threshold cur-
rent for non-zero firing and Ibias,i is the current coming from
other brain areas. Thus, after a specific threshold value of the
averaged afferent current, the neural population will be acti-
vated, and there is a linear relationship between the neural
firing rate and the overall afferent current. We shall later
show that this function fits the experimental data for Ox,
5-HT and NE neurons.
In general, the afferent current Ii can consist of several
different types of currents mediated by the different modu-
lators and their receptor subtypes. Each of these currents
will be determined by the corresponding neuromodulator
concentration levels and the receptor affinities (figure 2).For example, suppose a neuromodulator y from region j
induces a current I j!i on target region i, then we can describe
the dynamics of the current by
t j!i
dI j!i
dt
¼ I j!i þ Gj!ið½yÞ, (2:3)
where [y] is the neuromodulator concentration level, and t j!i
is the effective time constant owing to the applied neuro-
modulator which can be estimated from experiments. (If
there are more than one receptor subtypes mediated by the
same neuromodulator over the same brain regions, then we
can specify the above variables further, e.g. by defining
t j!i,R and I j!i,R for a receptor subtype R.) The value of t j!i
can be deduced from the response dynamics of the induced
current (or neural firing rates, if the induced current data
are not available) upon infusion of specific neuromodulator
at the targeted neurons. The input–output function Gj!i
can be described by the sigmoid-like function commonly
used in pharmacology [59]
Gj!ið½yÞ ¼ p j!i,LR
þ p j!i,UR
1þ exp( log10ð½y þ p j!i,LSÞ=p j!i,SÞ
, (2:4)
where p j!i,LR and p j!i,UR determine the range of the neuro-
modulatory effect on the currents, and p j!i,LS and p j!i,S
control the lateral shift and the slope of the neuromodulator
response current function, respectively. The values of these
parameters will be fitted to experimental data through
firing rate–neuromodulator concentration or firing rate–
current relationships. We used the standard nonlinear
regression method, nlinfit from Matlab (The MathWorks
Inc., Natick, MA, 2000). This approach particularly allows
us to circumvent the complexity of actually simulating the
intracellular signal transduction at the post-synaptic neurons.
This post-synaptic current depends upon the extracellular
neuromodulator release which is, in turn, dependent on the
(pre-synaptic) neural population firing rate of the source
neurons. Thus, to close the loop in the model, we have to
mathematically describe how the release-and-reuptake
dynamics are affected by the neural firing rate of the neuro-
modulator source. We follow a mathematical form similar
to that estimated from voltammetric measurements [40]:
d½y
dt
¼ ½y p,j!i fj 
Vmax½y
Km þ ½y , (2:5)
where ½y p,j!i is the per stimulus [y] release (at the targeted
area i from source j ). The rightmost term in equation (2.5)
represents the reuptake rate, and is approximated from
the Michaelis–Menten equation. Here, Km and Vmax are the
Michaelis–Menten constants, with Vmax defined as the maxi-
mum uptake rate and Km is the substrate concentration where
the uptake proceeds at half of the maximum rate. The value
for both of these parameters can be obtained from exper-
iments [40]. In voltammetry experiments, fj is typically an
artificially applied high current stimulus frequency to stimu-
late the release of y. However, following our previous work
[60], we can redefine it as the neural firing frequency of the
neuromodulator source. Hence, the value of ½y p,j!i has to
be adjusted from that in voltammetry experiments, and the
exact value in the model can be obtained by constraining
the overall basal activity levels of the system to be within
the observed experimental ranges (see below).
Table 1. Basal ﬁring rate, neurotransmitter levels, dynamical time constants, and other model parameters for the LHA–DRN–LC circuits. Asterisk: [39],
assuming Vmax, and per stimulus release at dorsal lateral geniculate (DLG) and LC will be same. Hash: [40]. Plus: parameter values are tuned to obtain the
basal values close to those in experiments.
parameter description value reference, remarks
fDRN basal ﬁring rate of 5-HT neurons in DRN 0.8 Hz [41], in vitro
fLC basal ﬁring rate of NE neurons in LC 2.15 Hz [42], in vitro
fLHA basal ﬁring rate of Ox neurons in LHA 2.3 Hz [37], in vitro
kLHA gain of the input–output function for
LHA neurons
0.2 Hz pA21 [43]
KDRN gain of the input–output function for
DRN neurons
0.033 Hz pA21 [10,44,45]
kLC gain of the input–output function for
LC neurons
0.058 Hz pA21 [46]
I0,LHA threshold current for non-zero ﬁring of
LHA neurons
0 pA [43]
I0,DRN threshold current for non-zero ﬁring of
DRN neurons
24.82 pA [10,44,45]
I0,LC threshold current for non-zero ﬁring of
LC neurons
0.028 pA [46]
Ibias,LHA afferent current to LHA neurons 11.5 pA [43]
Ibias,DRN afferent current to DRN neurons 24.82 pA [10,44,45]
Ibias,LC afferent current to LC neurons 37.41 pA [46]
[5-HT]LHA basal [5-HT] level in Ox neurons 1.6 nM [47]
[5-HT]LC basal [5-HT] level in Ne neurons 6.7 fM min
21
approximately 0.11 fM s21
[48]
[NE]DRN basal [NE] level in 5-HT neurons 500 pg mg
21
approximately 2.95 mM
[49], assuming baseline
5-HT levels at dorsal and
rostral raphe are same
[NE]LHA basal [NE] level in Ox neurons 0.83 nM [50], assuming baseline NE
levels at hypothalamus and
LHA are the same
[Ox]DRN basal [Ox] level in 5-HT neurons 10 pg mg
21
approximately 3.4 nM
[51], assuming baseline Ox
level at pons and DRN are
the same
[Ox]LC basal [Ox] level in Ne neurons 2 pg mg
21
0.56 nM
[51]
t[5-HT] ! LHA time constant of the effect of [5-HT] on
Ox neurons
2 s [36]
t[5-HT] ! LC time constant of the effect of [5-HT] on
Ne neurons
20 s [52]
t[Ox] ! DRN time constant of the effect of [Ox] on
5-HT neurons
60 s [53]
t[Ox] ! LC time constant of the effect of [Ox] on
Ne neurons
20 s [54]
t[NE] ! DRN time constant of the effect of [NE] on
5-HT neurons
20 s [55]
t[NE] ! LHA time constant of the effect of [NE] on
Ox neurons
1 s [56]
(Continued.)
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Table 1. (Continued.)
parameter description value reference, remarks
Vmax,[NE] ! LC maximum uptake rate for the [NE] release in
LC neurons
74 nM s21 *
Km,[NE] ! LC substrate concentration for the [NE] release in
LC neurons
400 nM *
Vmax,[NE] ! DRN maximum uptake rate for the [NE] release in
DRN neurons
74 nM s21 *
Km,[NE] ! DRN substrate concentration for the [NE] release in
DRN neurons
400 nM *
Vmax,[NE] ! LHA maximum uptake rate for the [NE] release in
LHA neurons
74 nM s21 *
Km,[NE] ! LHA substrate concentration for the [NE] release in
LHA neurons
400 nM *
Vmax,[5-HT] ! DRN maximum uptake rate for the [5-HT] release
in DRN neurons
1800 nM s21 #
Km,[5-HT] ! DRN substrate concentration for the [5-HT] release
in DRN neurons
170 nM #
Vmax,[5-HT] ! LHA maximum uptake rate for the [5-HT] release
in LHA neurons
1800 nM s21 #
Km,[5-HT] ! LHA substrate concentration for the [5-HT] release
in LHA neurons
170 nM #
Vmax,[5-HT] ! LC maximum uptake rate for the [5-HT] release
in LC neurons
1800 nM s21 #
Km,[5-HT] ! LC substrate concentration for the [5-HT] release
in LC neurons
170 nM #
a[Ox] ! LC rise factor for [Ox] release in LC neurons 0.2314 nM þ
h[Ox] ! LC decay rate for [Ox] release in LC neurons 0.85 s21 þ
a[Ox] ! DRN rise factor for [Ox] release in DRN neurons 1.405 nM þ
h[Ox] ! DRN decay rate for [Ox] release in DRN neurons 0.85 s21 þ
[5-HT]p,LHA per-stimulus [5-HT] release in LHA neurons 12.14 nM þ
[5-HT]p,LC per-stimulus [5-HT] release in LC neurons 0.852 fM þ
[NE]p,DRN per-stimulus [NE] release in DRN neurons 27.272 nM þ
[NE]p,LHA per-stimulus [NE] release in LHA neurons 0.0642 nM þ
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tal data, particularly its release and reuptake dynamics.
Hence, we adopt the simplest mathematical form to describe
the [Ox] dynamics [60], with only two parameters:
d[Ox]
dt
¼ a fLHAh½Ox, (2:6)
where a is the rise factor and h is a constant decay rate, and
both considered to be free parameters. The value of a is
selected, so that the release of [Ox-A/B] at DRN or [Ox-A]
at LC is close to the observed basal value (table 1).
A summary of the general model construction process is
summarized in figure 2. Such a modelling approach can allow
multiple brain regions to be constructed, simulated and ana-
lysed. (See Methods for a simpler approach when only two
brain regions are considered.)Overall,we have proposed an effi-
cient and scalable approach by incorporating neuromodulator
properties and dynamics into traditional firing-rate-typemodels. We shall next apply this approach to develop a neural
circuit model involving multiple interacting neuromodulators.
2.2. An example with three interacting
neuromodulators
We shall now demonstrate, as an example, the steps towards
developing a neural circuit model of three interacting neuro-
modulator systems (lateral hypothalamus, DRN and LC)
through three corresponding neuromodulators (Ox, 5-HT
and NE), based on available experimental data and equations
(2.1)–(2.6). These brain regions were chosen mainly because
(i) they consist of different neuromodulator systems that
can directly influence each other, (ii) they were targets of
existing drugs, and (iii) we can demonstrate how one could
model with incomplete information. It is important to bear
in mind that different datasets from various experiments
are used for model construction and validation.
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Figure 3. Fitted input–output functions. (a,b) Effects of concentrations [Ox-A/B] and [NE] on DRN neurons. (c,d) [Ox-A] and [5-HT] on LC neurons. (e,f ) [5-HT] and
[NE] on LHA neurons. Estimated function (pink) is based on f– I curves and current input–output functions.
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the three brain regions are determined according to the avail-
able electrophysiological data ( f2 I curves and typical
baseline firing rate ranges). Using the threshold-linear function
(equation (2.2)), the fitted parameter values for the LC’s
NE neuronal f2 I curve are kLC ¼ 0:058 Hz pA1,
I0,LC ¼ 0:028 pA and Ibias,LC ¼ 37:41 pA [46]; that for DRN’s
5-HT neuron are kDRN ¼ 0:033 Hz pA1, I0,DRN ¼ 0:13 pA
and Ibias, DRN ¼ 24:82 pA [10,44,45]; and that for LHA’s Ox
neuron are kLHA ¼ 0:2 Hz pA1, I0,LHA ¼ 0 pA and
Ibias, LHA ¼ 11:5 pA [43].
Next, parameters of the induced currents and associated G
functions are fitted to the experimental data through the
concentration–response relationships for the change in firing
rate induced by the neuromodulator. For example, the total
afferent current induced by neuromodulators on DRN’s neur-
ons can be rewritten as a sum: IDRN ¼ ILHA!DRN þ ILC!DRN.
The terms on the right are the currents owing to Ox-A/B
from LHA and NE from LC (for simplicity, we ignore the cur-
rent owing to autoreceptors and interneurons within each brain
region, see [17,61]). The dynamics for each induced current are
dependent on the concentration of the neuromodulator.
The Ox-induced current on DRN neurons (when NE-induced
current on DRN is clamped) can be described by
tLHA!DRN
dILHA!DRN
dt
¼ ILHA!DRN
þ GLHA!DRNð½OxÞ, (2:7)
where tLHA!DRN is the effective time constant owing to the
injected Ox deduced from experiments. The GLHA!DRNfunction (from equation (2.4), with units of currents) par-
ameters are fitted to experimental data [53], such that
pLR ¼ 0 pA, pUR ¼ 65 pA, pLS ¼ 2:08 nM, pS ¼ 0:452 nM
and tLHA!DRN ¼ 60 s. With these values, we obtain the best
fit for the overall firing rate–concentration function
(figure 3a), having the induced currents becoming an implicit
function.
Similarly, we can obtain the parameter values for the
other currents: ILC!DRN, ILHA!LC and IDRN!LC. The fitted
parameter values for ILC!DRN are pLR ¼ 0 pA, pUR ¼ 57 pA,
pLS ¼ 3:7 nM, pS ¼ 0:193 nM and tLC!DRN ¼ 20 s (figure 3b)
[55]. Parameter values for the incoming current from LHA
to LC neurons ILHA!LC are found to be pLR ¼ 3:8 pA,
pUR ¼ 54 pA, pLS ¼ 2:3 nM, pS ¼ 0:341nM and
tLHA!LC ¼ 20 s [62] (figure 3c). For IDRN!LC: pLR ¼ 0 pA,
pUR ¼ 40 pA, pLS ¼ 4:214nM, pS ¼ 0:347 nM and
tDRN!LC ¼ 20 s (figure 3d). With these parameter values, we
were able to obtain reasonable fits with respect to experiments
for the various input–output functions.
We now proceed to model the effects of 5-HT on LC’s
NE neurons. However, there is a lack of experimental data
on the direct effects of 5-HT on LC’s NE neurons (exper-
iments typically focused on how different 5-HT2 receptor
agonists affect the firing rate of LC neurons [63]). Thus, to
estimate the 5-HT-dependent input–output function of
firing frequency, we approximate the input–output function
from other experimental data by restricting the basal activi-
ties to [5-HT]  0.11 fM and fLC  2.15 Hz (table 1). We
considered the same sigmoidal shape (as defined in equation
(2.4)) for all the neuromodulator-dependent firing-rate
f DR
N
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Figure 4. Single trial activity dynamics under baseline condition. (a) Firing rate of DRN neural population. (b,c) Concentration level of 5-HT in the LHA and LC areas.
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Hj!ið½yÞ ¼ q j!i,LR
þ q j!i,UR
1þ exp(log10ð½y þ q j!i,LSÞ=q j!i,SÞ
, (2:8)
where q j!i,LR and q j!i,UR determine the range of the neuro-
modulatory effect on the firing rate, and q j!i,LS and q j!i,S
control the lateral shift and the slope of the neuromodulator
concentration-dependent firing-rate function Hj!i, respect-
ively. Considering these baseline values, the estimated
parameter values are qLR ¼ 2:15 Hz, qUR ¼ 2:15 Hz,
qLS ¼ 4:273 nM and qS ¼ 0:3 nM [42].
Similar to the 5-HT modulating effect on LC, the 5-HT
response direct firing–frequency curve was not available
for LHA neurons. Thus, we approximate the input–output
function from other experimental data [37,47] and restricting
the basal activities to [5-HT]  1.6 nM and fLHA  2:3Hz.
Then, the estimated parameter values are qLR ¼ 2:3Hz,
qUR ¼ 2:3Hz, qLS ¼ 0:9 nM, qS ¼ 0:1 nM [36]. Then,
we approximated the parameters for IDRN!LHA to be:
pLR ¼ 0 pA, pUR ¼ 36 pA, pLS ¼ 1:55 nM and pS ¼ 0:4 nM.
With these values, we observe that there is no Ox neuronal
firing even for 10 mM of [5-HT] (figure 3e). This is due to
the strong inhibition caused by the induced inward GIRK
current (approx. 32 pA), which eventually saturates (at
approx. 35 pA) for higher [5-HT] levels.
As the model has a hard threshold in the f–I curve,
there is a sharp change within the 10–100 nM of [5-HT].
Thus, we could not obtain a perfect fit for the functions
GDRN!LHAð½5-HTÞ and hence the fLHA  ½5-HT curve. Simi-
larly, the fitted parameters for the NE-induced GIRK
currents on LHA, ILC!LHA, are pLR ¼ 0 pA, pUR ¼ 120 pA,
pLS ¼ 5:39nM, pS ¼ 0:4 nM and tLC!LHA ¼ 1 s [56]. We
encounter a similar issue for higher [NE] level, i.e. no perfect
fit for GLC!LHAð½5-HTÞ (figure 3f ).
Compared with the effect of 5-HT on the target areas, esti-
mating the parameter values (q’s) for the effect of NE/Ox on
the target areas was relatively straightforward. As experimental
data related to neuromodulator-dependent firing-rate input–
output function were available, we approximated the q-values
for the Ox effect of DRN as qLR ¼ 0:8Hz, qUR ¼ 2:2Hz,
qLS ¼ 2:072 nM, qS ¼ 0:4463 nM [62]. q-values for the
Ox effect of LC are qLR ¼ 2:35Hz, qUR ¼ 3:15Hz,
qLS ¼ 2:3066 nM, qS ¼ 0:3468 nM [62]. Similarly, q-values
for the NE effect of LHA are estimated as qLR ¼ 2:3Hz,
qUR ¼ 2:3Hz, qLS ¼ 4:235 nM, qS ¼ 0:302 nM [56]. For NE
effect on DRN they are qLR ¼ 0:8Hz, qUR ¼ 0:193Hz,
qLS ¼ 3:711 nM, qS ¼ 0:208 nM [64].
After determining the input–output functions and
dynamics for all the currents, the final step is to integrate
all three brain regions and their interactions. In general, theactivities for the combined system will be different from the
individual isolated systems. Thus, the baseline activities of
the coupled system will be different from that observed
from the individual systems. However, the remaining set of
parameters, the neuromodulator release per stimulus fre-
quencies, i.e. the [y]p’s, can be adjusted to resolve this. We
found that for values of ½5-HT p,LHA, [5-HT] p,LC, [NE] p,DRN
and [NE] p,LHA at 12:14 nM, 0:852 fM, 27:272 nM and
0:0642 nM, respectively, and Ox rise factor and decay rate
(a and h) for DRN are 1.405 and 0.85 l s21 while for LC are
0.2314 nM and 0.851 s21, the overall basal firing rates and
concentration levels are reasonably within the experimental
ranges (table 1). Note that the baseline activities are obtained
after sufficiently long simulation to attain their (stable) steady
states (see figure 4 for a sample trial).
After successfully constructing the LHA–DRN–LC circuit
model, we shall demonstrate simulating neuropharmacologi-
cal drug effects in the system. In particular, we shall focus
on effects of Ox-1 receptor antagonist (SB-334867-A), SSRIs
and/or SNRIs on the LHA–DRN–LC circuit.2.3. Drug effect simulations
Pharmacologically, antagonists can be classified into two
categories: competitive and irreversible antagonists [65].
Pre-treatment or application of competitive antagonist can
shift the baseline dose–response curve horizontally. This
shift towards the higher doses (of neurotransmitter) increases
the effective dose (ED50) value of the dose–response curve
(where 50% of the maximal response of the dose is being
observed). Conversely, application of an irreversible antagon-
ist can cause shifts in the maximum range of the antagonist
effect and does not affect the ED50 value [66].
Ox-1 receptor antagonists have been suggested to encou-
rage sleep, as well as treatment and prevention of many
psychiatric disorders [67]. In particular, the Ox-1 receptor
antagonist, SB-334867-A, acts as a competitive antagonist
which rightward shifts the Ox-A response curve in 5-HT
and NE neurons in DRN and LC [62,68]. Thus, we can
easily incorporate the effect of SB-334867-A, by simply
laterally shifting the function GLHA!DRN=LC ð½Ox AÞ.
Selective serotonin/norepinephrine reuptake inhibitors
(SSRIs/NRIs) are some of the commonly known pharmaco-
logical agents that are used for the treatment of various
psychiatric disorders. The basic (acute) actions of these
drugs are similar: primarily to increase the extracellular con-
centration level of their respective neuromodulator
concentration by inhibiting the uptake process and reduce
the synaptic clearance in the extracellular space [69]. There
have been numerous studies conducted to understand the
effects of uptake inhibitors on [5-HT] uptake [69,70]. In
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Figure 5. Effects of substrate concentration factor Km,[5-HT] and Km,[NE], and ½Ox-A antagonist SB-334867-A on the firing rates and concentration levels in the circuit.
Each panel varies both Km,[5-HT] and Km,[NE] values to simulate the effects of drugs and their combinations. Km,[NE] ¼ 400 nM (control basal value).
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inhibitors can affect the values of the Michaelis–Menten
constants Km and Vmax in the limbic part of the brain.
For example, 10 mM of fluoxetine, an SSRI (when applied to
the substantia nigra area), increased the value of Km by
about a factor of 5 but did not alter the value of Vmax signifi-
cantly [69]. Thus, to incorporate the influence of SSRIs/NRIs
in our model, we can mimic the different doses of SSRIs by
varying the different values of Km. For simplicity, our
model will ignore chronic or other long-term secondary
actions such as receptor density changes.
As we increase the value of Km,[5-HT] (mimic SSRI), [5-HT]
linearly increases in both the targeted areas LHA and LC
(figure 5a,h solid blue). This increase in [5-HT] level causes
a significant decrease in fLHA (figure 5c, solid blue), which
is consistent with experimental findings [36]. This in turn
causes a decrease in [Ox-A/B] levels in the DRN and LC
areas (figure 5d,g solid blue). Interestingly, because of the net-
work effect, there is a subsequent decrease in fDRN (figure 5f,
solid blue), consistent with [71] even when we did not incor-
porate any inhibitory 5-HT autoreceptors [72,73]. However,
5-HT’s effect on LC’s NE neurons is minimal, consistent
with [74], and therefore, fLC does not alter the [NE] levels
in the DRN and LHA significantly (figure 5i, solid blue).
These effects remained to be validated in the intact brain.
Next, we simulate the combined effects of SSRIs and
NRIs, by increasing the value of Km,[NE] to three and five
times its control value (400 nM) while varying Km,[5-HT] as
previously. The model shows that for higher values of
Km,[NE] more [5-HT] and [NE] are released in the targeted
areas in the LHA and LC when compared with controls
(figure 5a,h dashed red and dotted-dashed pink). This
suggests that other than Km,[5-HT], [NE] release in DRN alsohelps stimulate the release of [5-HT] in these targeted areas,
consistent with [75]. This rise in the [5-HT] level significantly
affects fLHA, ½Ox A=BDRN, [Ox A]LC, ½NEDRN and
½NELHA while there is little impact on fLC (figure 5b–e,g,i).
Finally, to assess the combined effect of SSRIs, NRIs and
SB-334867-A, we set Km,[NE] to be five times the control value
and mimic the influence of 10 mM SB-334867-A on DRN and
LC (by changing the pLR value from 3.8 to 2 pA, pUR from
54 to 51 pA, shift factor pLS from 22.3 to 24.192 nM, and
slope factor pS from 0.341 to 0.592 in LC). For DRN, pLS is
changed from 22.08 to 22.97 nM and pS from 0.452 to
0.367. We find that this triple-drug combination can cause
a further decrease in the fDRN and fLC, and a substantial
reduction in [NE]DRN levels (figure 5e,f,i solid green),
whereas the rest are not significantly affected by the addition
of SB-334867-A (figure 5a–d,g,h solid green).2.4. Software for model simulation and visualization
Using Matlab, we have designed and developed a software,
called ‘NModC’ (neuromodulator circuit), with friendly
graphical user interface (GUI) for simulation, analysis and
visualization of the types of models described. The software
is easy to use, and can easily be generalized to additional
brain regions, other neural subpopulations and neuromodu-
lator types. The user can visualize the activities of multiple
brain regions dynamically and simultaneously. These brain
regions are embedded in a rotatable three-dimensional glass
brain using standard Montreal Neurological Institute (MNI)
coordinates (figure 6a). The user can also further specify
brain regions of interest to find the dynamical variables’
time courses and mutual relationships (figure 6b) for more
detailed analysis. The model parameters can be easily altered
(a)
(c)(b)
Figure 6. Screenshot of the NModC software. A user-friendly GUI of neuromodulator neural circuit model that can simulate, analyse, visualize and edit. (a) Users can
run the model to visualize the results within a rotatable three-dimensional glass brain after pressing the ‘Start’ button. The user can stop the simulation using the
‘Stop’ button. Simulation time parameters can be controlled using ‘Time’ and ‘Sim scale’, and the GUI can be closed using ‘Close’ buttons. (b) Model variables’ time
courses and their mutual relationships can be observed using the ‘Outputs’ button. (c) Model variables’ exact values can be found and model parameters edited
upon pressing the ‘Parameters’ button. ‘Default’ returns to default model parameters and ‘Simulate’ re-runs the model after editing the parameter values.
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transients of neuromodulator concentration level and firing
rates, and can also compare the firing rates of the two brain
regions (figure 6c). Further details are described in the
Methods section, and the software is available at https://
github.com/vyoussofzadeh/NModC.3. Discussion
In this work, we have proposed a new computational model-
ling framework for incorporating essential biological features
of neuromodulation in neural circuits. This provides acomputational platform to link from low-level neurobiology
to large-scale brain activities.
Our framework is based on the population-averaged firing-
rate type of model which hasmodel parameters constrained by
neurobiology. This is to be compared with other firing-
rate-type models without such constraints [14–16]. The
model integrates pharmacological and electrophysiological
data from separate experimental studies to constrain the
input–output neuronal functions, and also the timescale and
profile of the effective neuromodulator-induced currents.
Another key difference in our modelling approach is the
consideration of the release-and-reuptake/decay dynamics
of the extracellular neuromodulator concentration level
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cumvented modelling the complex intracellular biochemical
processes, but instead, directly modelled the concentration-
dependent effect on neural firing rate activity based on
pharmacological–electrophysiological data.
In particular, to allow our approach to be generalizable
to multiple interacting brain regions, we introduced neuro-
modulator-induced currents to bridge the gaps between
neuromodulator concentration levels and targeted neural firing
rate activities—afferent influences from different brain regions
can be accounted for by their summed currents. The timescale
and response curve of the neuromodulator concentration-
dependent currents were constrained by data from combined
pharmacological and electrophysiological experiments.
We demonstrated our modelling approach with the
example of a neural circuit that involves three mutually inter-
acting brain regions (LHA, DRN and LC), which are also
sources of three different neuromodulators: orexin, serotonin
and NE, respectively. The transient and steady-state dynamics
of the experimentally measurable variables (neural firing rates
and neuromodulators’ extracellular concentration levels) could
be easily simulated. In particular, our model supported the
coexistence of the observed (steady-state) baseline firing rates
and neuromodulator levels found in separate experiments.
An important application of our model was the prediction
of the effects of neuropharmacological drugs on neural circuits.
We simulated the effects of SSRIs, NRIs and Ox-1 receptor
antagonist on the LHA–DRN–LC model. We first showed
that SSRIs could have a wide effect on the neural circuit,
except the LC–NE system. Interestingly, SSRI could inhibit
the DRN (decrease in fDRN), the source of 5-HT, even though
we did not implement its inhibitory autoreceptors. This effect
was essentially owing to the direct effects on serotonin hetero-
receptors on the LHAandLC,which in turn inhibited theDRN.
Similar circuit-based effects could be explained for the addition
of NRIs and/or Ox-1 receptor antagonists.
The constructed LHA–DRN–LC circuit model turned out
to be dominated by a unidirectional influence between any
pair of interacting brain areas (figure 5). Hence, these result
in monotonic relationships (either increased or decreased)
as the model parameters (e.g. Km’s) were varied. However,
this need not generally be the case. For example, a more
balanced (especially excitatory–inhibitory) coupled network
could easily lead to emergent circuit oscillations or even
non-monotonic effects [8,76]. In the latter case, it might
then be possible to search for the optimal drug dosage. In
fact, we had shown evidence of such nonlinear emergent be-
haviour when the model incorporated autoreceptors and
non-principal (e.g. inhibitory GABAergic) interneurons (to
mediate indirect connections) [17]. Moreover, the excit-
atory–inhibitory balance of the network can also be
influenced by the co-release of the neurotransmitters (e.g.
glutamate) [77,78]. In this case, our framework can still
accommodate this by introducing additional dynamical
equations to describe the effects of glutamate or GABA (for
the same pre-synaptic firing rate).
Our work has also shown that administration of multiple
drugs (serotonin/NE reuptake inhibitors and Ox-A antagon-
ist) simultaneously can be simulated in neural circuits to
search for the optimal mixture of drugs. However, the results
remain to be validated as there is a lack of such work done in
experiments. Hence, this will form model predictions that can
help experimentalists in designing future studies. Forexample, multielectrode array in vivo recordings can be
designed to study the wide-ranging effects of drugs on differ-
ent brain areas. It would also be interesting to use the model
to minimize the side effects of drugs, which is an important
issue in neuropharmacology.
Our modelling framework is scalable to incorporate mul-
tiple brain regions and hence can be used to study large-scale
brain effects. This includes studying the changes in REM/
non-REMstages or sleep–wake cycle [15,16], cortical dynamics
[8] and cognitive–emotional processing [8,76]. This would
require extending our current GUI software by including cor-
tical brain structure and their connectivity with the
neuromodulator sources. Thus, these models could poten-
tially reveal insights into the relationships among various
brain and behavioural disorders (depression, addiction, anti-
depressants and sleep disorders). Importantly, neuroimaging
data, especially from positron emission tomography and
functional magnetic resonance imaging, could potentially
be incorporated into our modelling framework, bridging
across multiple scales and modalities, similar in spirit to the
popular dynamic causal modelling approach [79]. Interest-
ingly, recent whole brain molecular imaging (functional
magnetic resonance imaging (MRI)) of serotonin transporter
to characterize 5-HT dynamics in humans before and after
(e.g. SSRI) drug administration is now possible [80], opening
up another possible application of our modelling framework.
In summary, we have proposed a promising new compu-
tational modelling framework that can integrate various
experimental neurobiological data into a computationally
efficient large-scale neural circuit model for simulating, test-
ing and predicting the effects of multiple endogenous
neuromodulators and neuropharmacological drugs.4. Methods
4.1. A simpler modelling approach for modelling two
brain regions
Note that if one is only interested in the mutual interactions of
two brain regions, then one may ignore the induced current
implementation step (figure 2, second column), and directly
model the influence of [y] on the firing rates fi [60], i.e.
t j!i
dfi
dt
¼ fi þ Kið½yÞ, (4:1)
where t j!i is the effective time constant owing to the injected
neuromodulator y on the ith neural population. Ki([y]) can
follow a similar form as the G function in equation (2.4).4.2. Model parameter and baseline values
A summary of the LHA–DRN–LC model parameter values and
baseline activities are shown in table 1.4.3. Numerical simulations
The neural circuit model simulation for the interaction of the
three brain areas is computed by using the forward Euler
numerical integration method which is applied to the set of the
first-order differential equations. A time step of 1 ms was
used. Smaller time steps were tested without affecting the
results. These simulations can also be extended to other (e.g.
second-order or fourth-order Runge–Kutta) numerical schemes.
Simulations were run until stable steady states are obtained.
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To begin the software, the user presses the ‘Start’ button on the
starting window of the GUI. This will result in the model outputs
of the interacting brain regions (figure 6a). The outputs appear in
the form of normalized neural (firing rate) at the specified brain
regions, e.g. red colour represents relatively higher activity,
whereas blue colour represents lower activity. The range of the
colour map is based on the absolute range of [0 255] Hz. These
colours of activity can change over time, reflecting their
dynamics. The regions are embedded in locations based on the
MNI coordinates in a glass brain. Three-dimensional rotation of
the brain is also allowed in the software. Although the structure
of the glass brain is currently based on normal human MRI data,
it can be easily replaced by an animal (e.g. rodent) glass brain
using the appropriate brain atlas.
Once the model is converged after simulation, upon clicking
on the ‘Outputs’ button in the starting window, the dynamical
variables for the selected regions will appear in a new window
(figure 6b). The variables are the (absolute) neural firing rates
and neuromodulator concentrations of the selected brain regions.
Both the individual variable’s temporal dynamics and mutual
relationships between the variables can be plotted. Upon clicking
the ‘Parameters’ button in the starting window, a new window
appears in which the model parameter values and the initial
numerical values of the variables are shown. The model par-
ameter values can be edited within this window. Once this is
done, the user can resimulate the new model by pressing the
‘Simulate’ button within the same window. This generates the
transients of baseline firing rates and concentration levels and
shows the relationship among them (e.g. firing rates). For defaultvalues, all the transient activities eventually attain their stable
steady states. These steady-state values of the system parameters
vary as we change the model parameters. For example, to mimic
the complex drug effects of SSRIs, Km is varied and correspond-
ing changes in the steady-state values are analysed separately
(see §2.3). If a mistake is made, then the user can always retrieve
back the initial values of the parameters by clicking on the
‘Default’ button.Authors’ contributions. A.J., T.M.M., G.P. and K.W.-L. conceived the com-
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